Prospects for immunisation against Marburg and Ebola viruses.

Reviews in Medical Virology
Thomas W GeisbertHeinz Feldmann

Abstract

For more than 30 years the filoviruses, Marburg virus and Ebola virus, have been associated with periodic outbreaks of hemorrhagic fever that produce severe and often fatal disease. The filoviruses are endemic primarily in resource-poor regions in Central Africa and are also potential agents of bioterrorism. Although no vaccines or antiviral drugs for Marburg or Ebola are currently available, remarkable progress has been made over the last decade in developing candidate preventive vaccines against filoviruses in nonhuman primate models. Due to the generally remote locations of filovirus outbreaks, a single-injection vaccine is desirable. Among the prospective vaccines that have shown efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant VSV (rVSV), were shown to provide complete protection to nonhuman primates when administered as a single injection. The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure.

References

Jan 1, 1978·Experimental Cell Biology·R M ZinkernagelJ J Holland
Feb 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·A H HaleH N Eisen
Sep 1, 1988·The American Journal of Tropical Medicine and Hygiene·E QuirozR B Tesh
Jan 1, 1987·The American Journal of Tropical Medicine and Hygiene·J S ReifG Cholas
Jan 26, 1996·Journal of Biotechnology·G M IgnatyevE A Kashentseva
Sep 5, 1998·The Journal of Infectious Diseases·M BrayJ Huggins
Feb 13, 1999·The Journal of Infectious Diseases·B M ConnollyP B Jahrling
Apr 10, 1999·Journal of Virology·A RobertsJ K Rose
Mar 4, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·T W GeisbertP B Jahrling
May 2, 2000·Current Pharmaceutical Design·M M Hitt, J Gauldie
Oct 24, 2001·Vaccine·M HeveyA L Schmaljohn
Dec 1, 2001·Expert Opinion on Biological Therapy·S Schlesinger
Apr 23, 2002·Journal of Virology·Takeshi NodaYoshihiro Kawaoka
May 9, 2002·Emerging Infectious Diseases·Thomas W GeisbertPeter B Jahrling
Sep 5, 2002·Reviews in Medical Virology·Jonathan O RaynerKurt I Kamrud
Jun 7, 2003·The Pediatric Infectious Disease Journal·Ruth A KarronJoanna M Tatem
Aug 9, 2003·Expert Review of Vaccines·Kenneth Lundstrom
Jan 22, 2004·FEMS Immunology and Medical Microbiology·Dana L SwensonM Javad Aman
May 18, 2005·Virus Research·Dennis SlateRichard B Chipman
Aug 9, 2005·Trends in Biotechnology·Leonard K PattendenDaniel I Lipin
Sep 16, 2006·Journal of Virology·Kathleen M Daddario-DiCaprioSteven M Jones
Jan 24, 2007·PLoS Pathogens·Heinz FeldmannThomas W Geisbert
Jan 24, 2007·PLoS Pathogens·Wendelien B OswaldDennis R Burton

❮ Previous
Next ❯

Citations

Dec 7, 2011·Proceedings of the National Academy of Sciences of the United States of America·Waranyoo PhoolcharoenMelissa M Herbst-Kralovetz
Jan 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·Andrea MarziIlhem Messaoudi
Oct 19, 2011·The Journal of Infectious Diseases·Andrea MarziHeinz Feldmann
Jul 5, 2012·PLoS Neglected Tropical Diseases·Adam MacNeil, Pierre E Rollin
Dec 25, 2013·PLoS Neglected Tropical Diseases·Chad E MireThomas W Geisbert
Dec 24, 2011·Future Microbiology·Andrew S Kondratowicz, Wendy J Maury
Nov 3, 2011·Future Virology·Masfique MehediHideki Ebihara
Dec 4, 2012·Viruses·Kristina BrauburgerJudith Olejnik
Nov 6, 2013·Immunotherapy·Erica Ollmann Saphire
Apr 25, 2012·Journal of Global Infectious Diseases·Vanessa N Raabea, Matthias Borcherta
Aug 22, 2014·Science Translational Medicine·Emily P ThiThomas W Geisbert
Mar 29, 2011·Expert Opinion on Drug Delivery·Fabian BlankChristophe von Garnier
Jan 18, 2011·Expert Opinion on Investigational Drugs·Aarthi NarayananKylene Kehn-Hall
Nov 19, 2014·Proceedings of the National Academy of Sciences of the United States of America·Charles D MurinErica Ollmann Saphire
Sep 20, 2011·Virus Research·Rebecca J Grant-KleinConnie S Schmaljohn
Apr 3, 2016·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Yuchen Fan, James J Moon
Jun 13, 2015·The Journal of Infectious Diseases·Mallory WilletMatthias J Schnell
Apr 14, 2015·Infectious Diseases of Poverty·Haider GhazanfarAli Ghazanfar
Dec 24, 2014·The Journal of Allergy and Clinical Immunology·Robert LindbladThad Zajdowicz
Feb 11, 2015·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·V RougeronE M Leroy
Dec 17, 2014·Journal of Public Health Policy·Anthony Robbins, Ruth Berkelman
Nov 4, 2015·The Lancet Infectious Diseases·Michael OsterholmUNKNOWN Wellcome Trust-CIDRAP Ebola Vaccine Team B
Aug 30, 2014·Expert Review of Anti-infective Therapy·Thomas Hoenen, Heinz Feldmann
Mar 10, 2017·Scientific Reports·Peter D WalshMatthias J Schnell
Nov 7, 2017·The Journal of Clinical Investigation·Emily P ThiThomas W Geisbert
Apr 5, 2018·Scientific Reports·Haruhiko FujihiraTatsuro Irimura
May 1, 2013·Expert Review of Anti-infective Therapy·Christopher F Basler
Dec 18, 2010·Expert Review of Vaccines·Darryl FalzaranoHeinz Feldmann
Apr 28, 2017·Virus Genes·Pierce Reynolds, Andrea Marzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.